A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:3
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [31] True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era
    Lagana, Alessandro
    Trisolini, Silvia Maria
    Maglione, Raffaele
    Mahnaz, Shafii Bafti
    Imperatore, Stefano
    Vitullo, Diana
    Capria, Saveria
    BLOOD COAGULATION & FIBRINOLYSIS, 2024, 35 (01) : 37 - 42
  • [32] Maternal and fetal outcomes of pregnancy occurring after a diagnosis of immune-mediated thrombotic thrombocytopenic purpura
    Jenna Brown
    Bindu Potugari
    Marshall A. Mazepa
    Ruhail Kohli
    Alison R. Moliterno
    Robert A. Brodsky
    Jason A. Vaught
    Richard Burwick
    Shruti Chaturvedi
    Annals of Hematology, 2022, 101 : 2159 - 2167
  • [33] Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura COMMENT
    Maitta, Robert W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 225 - 226
  • [34] Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
    Coppo, Paul
    Joly, Berangere S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 725 - 727
  • [35] Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura
    De Waele, Laure
    Sakai, Kazuya
    Mancini, Ilaria
    Sinkovits, Gyoergy
    Falter, Tanja
    Inoue, Takashi
    Agosti, Pasquale
    Rossmann, Heidi
    Von Auer, Charis
    Tersteeg, Claudia
    Meyer, Simon F. De
    Joly, Berangere S.
    Veyradier, Agnes
    Coppo, Paul
    Fijnheer, Rob
    Peyvandi, Flora
    Prohaszka, Zoltan
    Laemmle, Bernhard
    Vanhoorelbeke, Karen
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 493 - 502
  • [36] Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study
    Yue, Cai
    Su, Jian
    Fan, Xiaohong
    Song, Li
    Jiang, Wei
    Xia, Jinghua
    Shi, Tao
    Zhang, Xuan
    Li, Xuemei
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [37] The HLA Variant rs6903608 Is Associated with Disease Onset and Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Caucasians
    Mancini, Ilaria
    Giacomini, Elisa
    Pontiggia, Silvia
    Artoni, Andrea
    Ferrari, Barbara
    Pappalardo, Emanuela
    Gualtierotti, Roberta
    Trisolini, Silvia Maria
    Capria, Saveria
    Facchini, Luca
    Codeluppi, Katia
    Rinaldi, Erminia
    Pastore, Domenico
    Campus, Simona
    Caria, Cinzia
    Caddori, Aldo
    Nicolosi, Daniela
    Giuffrida, Gaetano
    Agostini, Vanessa
    Roncarati, Umberto
    Mannarella, Clara
    Fragasso, Alberto
    Podda, Gian Marco
    Birocchi, Simone
    Cerbone, Anna Maria
    Tufano, Antonella
    Menna, Giuseppe
    Pizzuti, Michele
    Ronchi, Michela
    De Fanti, Alessandro
    Amarri, Sergio
    Defina, Marzia
    Bocchia, Monica
    Ceru, Silvia
    Gattillo, Salvatore
    Rosendaal, Frits R.
    Peyvandi, Flora
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 13
  • [38] Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease
    Bourdin, V.
    Fosse, Q.
    Lambotte, O.
    Joly, B.
    Coppo, P.
    Anguel, N.
    Labeyrie, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1459 - 1463
  • [39] Difficulties in Diagnosing Congenital Thrombotic Thrombocytopenic Purpura
    Klukowska, Anna
    Niewiadomska, Edyta
    Budde, Ulrich
    Oyen, Florian
    Schneppenheim, Reinhard
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (02) : 103 - 107
  • [40] Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab
    Pecoraro, Carmine
    Ferretti, Alfonso Vincenzo Salvatore
    Rurali, Erica
    Galbusera, Miriam
    Noris, Marina
    Remuzzi, Giuseppe
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (06) : 1067 - 1070